Anusha Nagari
Overview
Explore the profile of Anusha Nagari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tripathy S, Nagari A, Chiu S, Nandu T, Camacho C, Mahendroo M, et al.
Endocrinology
. 2024 Sep;
165(11).
PMID: 39283953
Estradiol (E2) and relaxin (Rln) are steroid and polypeptide hormones, respectively, with important roles in the female reproductive tract, including myometrium. Some actions of Rln, which are mediated by its...
2.
Tripathy S, Nagari A, Chiu S, Nandu T, Camacho C, Mahendroo M, et al.
bioRxiv
. 2024 Apr;
PMID: 38659934
Estradiol (E2) and relaxin (Rln) are steroid and polypeptide hormones, respectively, with important roles in the female reproductive tract, including myometrium. Some actions of Rln, which are mediated by its...
3.
Owen D, Kwon M, Huang X, Nagari A, Nandu T, Kraus W
Biol Reprod
. 2023 Sep;
109(6):965-981.
PMID: 37694817
The placenta is a dynamic organ that must perform a remarkable variety of functions during its relatively short existence in order to support a developing fetus. These functions include nutrient...
4.
Huang D, Camacho C, Martire S, Nagari A, Setlem R, Gong X, et al.
Cancer Res
. 2022 Apr;
82(13):2361-2377.
PMID: 35472077
Significance: This study identifies cancer-driving mutations in histones as sites of PARP1-mediated ADP-ribosylation in breast and ovarian cancers, providing a molecular pathway by which cancers may subvert the growth-regulating effects...
5.
Gadad S, Camacho C, Malladi V, Hutti C, Nagari A, Kraus W
Mol Cancer Res
. 2021 Jun;
19(10):1688-1698.
PMID: 34158394
Poly(ADP-ribose) polymerase-1 (PARP-1) has gained considerable attention as a target for therapeutic inhibitors in breast cancers. Previously we showed that PARP-1 localizes to active gene promoters to regulate histone methylation...
6.
Malladi V, Nagari A, Franco H, Kraus W
Bioinform Biol Insights
. 2020 Jul;
14:1177932220938063.
PMID: 32655276
The differentiation of embryonic stem cells into various lineages is highly dependent on the chromatin state of the genome and patterns of gene expression. To identify lineage-specific enhancers driving the...
7.
Murakami S, Li R, Nagari A, Chae M, Camacho C, Kraus W
Mol Cancer Res
. 2019 Sep;
17(12):2356-2368.
PMID: 31551256
The bromodomain family member proteins (BRD; BET proteins) are key coregulators for estrogen receptor alpha (ERα)-mediated transcriptional enhancers. The use of BRD-selective inhibitors has gained much attention as a potential...
8.
Kim D, Camacho C, Nagari A, Malladi V, Challa S, Kraus W
Mol Cell
. 2019 Jul;
75(6):1270-1285.e14.
PMID: 31351877
PARP inhibitors (PARPi) prevent cancer cell growth by inducing synthetic lethality with DNA repair defects (e.g., in BRCA1/2 mutant cells). We have identified an alternative pathway for PARPi-mediated growth control...
9.
Xi Y, Shi J, Li W, Tanaka K, Allton K, Richardson D, et al.
BMC Genomics
. 2018 Feb;
19(1):150.
PMID: 29458327
Background: Epigenetic regulators are frequently mutated or aberrantly expressed in a variety of cancers, leading to altered transcription states that result in changes in cell identity, behavior, and response to...
10.
Franco H, Nagari A, Malladi V, Li W, Xi Y, Richardson D, et al.
Genome Res
. 2017 Dec;
28(2):159-170.
PMID: 29273624
Noncoding transcription is a defining feature of active enhancers, linking transcription factor (TF) binding to the molecular mechanisms controlling gene expression. To determine the relationship between enhancer activity and biological...